Cardiology

Study links hs-cTnT to MACE, mortality in rheumatoid arthritis

For patients with rheumatoid arthritis (RA), a detectable level of high-sensitivity cardiac troponin T (hs-cTnT) is associated with increased risk of major adverse cardiovascular events (MACE) and all-cause mortality, according ...

Arthritis & Rheumatism

FDA expands pediatric indication for Rinvoq

The U.S. Food and Drug Administration has expanded indications for AbbVie's Rinvoq (upadacitinib) to now include pediatric patients (ages 2 years and older) with polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic ...

Arthritis & Rheumatism

The impact of lifestyle intervention in rheumatoid arthritis

EULAR—The European Alliance of Associations for Rheumatology—has previously made recommendations for lifestyle interventions in people with rheumatic and musculoskeletal diseases, including rheumatoid arthritis (RA). ...

Arthritis & Rheumatism

Encouraging cooperation in inflammatory arthritis

There is a need to improve cross-sectoral care for people with inflammatory arthritis. The Danish Centre for Expertise in Rheumatology (CeViG) at the Danish Hospital for Rheumatic Diseases in Sønderborg, Denmark, is a unique ...

Arthritis & Rheumatism

Self-management recommended for people with inflammatory arthritis

EULAR—The European Alliance of Associations for Rheumatology—recommends patient self-management for people with inflammatory arthritis. The intention is to empower people to acquire a good understanding of their disease ...

page 1 from 40

Rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic, systemic and serious inflammatory disorder that may affect many tissues and organs, but principally attacks the joints producing an inflammatory synovitis that often progresses to destruction of the articular cartilage and ankylosis of the joints. Rheumatoid arthritis can also produce diffuse inflammation in the lungs, pericardium, pleura, and sclera, and also nodular lesions, most common in subcutaneous tissue under the skin. Although the cause of rheumatoid arthritis is unknown, autoimmunity plays a pivotal role in its chronicity and progression.

About 1% of the world's population is afflicted by rheumatoid arthritis, women three times more often than men. Onset is most frequent between the ages of 40 and 50, but no age is immune. It can be a disabling and painful condition, which can lead to substantial loss of functioning and mobility. It is diagnosed chiefly on symptoms and signs, but also with blood tests (especially a test called rheumatoid factor) and X-rays. Diagnosis and long-term management are typically performed by a rheumatologist, an expert in the diseases of joints and connective tissues.

Various treatments are available. Non-pharmacological treatment includes physical therapy and occupational therapy. Analgesia (painkillers) and anti-inflammatory drugs, as well as steroids, are used to suppress the symptoms, while disease-modifying antirheumatic drugs (DMARDs) are often required to inhibit or halt the underlying immune process and prevent long-term damage. In recent times, the newer group of biologics has increased treatment options.

The name is based on the term "rheumatic fever", an illness which includes joint pain and is derived from the Greek word rheumatos ("flowing"). The suffix -oid ("resembling") gives the translation as joint inflammation that resembles rheumatic fever. The first recognized description of rheumatoid arthritis was made in 1800 by Dr Augustin Jacob Landré-Beauvais (1772-1840) of Paris.

This text uses material from Wikipedia, licensed under CC BY-SA